Product image of Maymetsi (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Maymetsi

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Maymetsi (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride / Sitagliptin, the active ingredients in Maymetsi, are a Biguanide and a DPP‑4 inhibitor presented as a fixed‑dose combination tablet for oral administration. The medication is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control elevated blood glucose levels when used as part of a comprehensive treatment plan that includes diet and exercise.

GNH India supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Manufacturer / TM Owner

Tad Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maymetsi, a fixed‑dose combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (initial therapy): provides glycemic control as first‑line treatment in combination with lifestyle measures.
  • Type 2 diabetes mellitus (add‑on therapy): enhances glucose lowering when metformin alone does not achieve target HbA1c.
  • Type 2 diabetes mellitus (metformin intolerance): offers an alternative to metformin monotherapy by combining a lower metformin dose with sitagliptin.

How It Works

  • Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity, thereby decreasing basal glucose output. Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in higher circulating incretin hormones (GLP‑1 and GIP). The increased incretins enhance glucose‑dependent insulin secretion and suppress glucagon release, together producing better post‑prandial and overall glycemic control.

Side Effects

Adverse reactions may occur with any antidiabetic therapy and should be monitored.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: frequent loose stools, often transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild tension‑type headache.
  • Hypoglycemia (when combined with sulfonylureas or insulin): symptoms of low blood sugar.
  • Metallic taste: occasional altered taste perception.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Acute pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
  • Hepatic dysfunction: abnormal liver enzymes or jaundice.
  • Renal impairment worsening: especially in patients with pre‑existing kidney disease.
  • Severe hypoglycemia: profound low glucose requiring assistance.

Precautions & Warnings

Patients should be evaluated for safety before initiating therapy.

  • Renal function assessment: ensure adequate glomerular filtration before prescribing.
  • Hepatic function monitoring: avoid use in severe liver disease.
  • Cardiovascular status: use caution in patients with congestive heart failure.
  • Elderly patients: start with lower doses and monitor for intolerance.
  • Concomitant medications: review for agents that may increase risk of hypoglycemia or lactic acidosis.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Potential drug interactions may affect efficacy or safety.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis.
  • Cimetidine: can increase metformin plasma concentrations.
  • Insulin or sulfonylureas: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin.
  • ACE inhibitors or ARBs: monitor renal function and potassium levels.
  • NSAIDs: can reduce renal perfusion, increasing metformin exposure.

Frequently Asked Questions

Maymetsi is a fixed‑dose oral tablet that combines metformin hydrochloride and sitagliptin. It is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a broader management plan that includes diet, exercise, and other antidiabetic agents when needed.

Metformin lowers glucose production by the liver and increases the body's sensitivity to insulin, while sitagliptin blocks the DPP‑4 enzyme, raising levels of incretin hormones that stimulate insulin release and suppress glucagon. Together they provide complementary mechanisms to reduce blood sugar levels.

The specific dose of Maymetsi is determined by the prescribing clinician based on the individual’s glycemic targets, renal function, and overall treatment plan. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

Safety of Maymetsi in pregnancy or while breastfeeding has not been fully established. Healthcare providers usually weigh the benefits against potential risks and may prefer alternative treatments. Patients should discuss any plans for pregnancy or lactation with their prescriber before using this medication.

To request Maymetsi, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maymetsi combines two established agents—metformin, a first‑line biguanide, and sitagliptin, a DPP‑4 inhibitor—offering dual mechanisms in a single tablet. Compared with metformin alone, it provides additional post‑prandial glucose control, and versus separate tablets it may improve adherence. It differs from sulfonylureas, which carry higher hypoglycemia risk.

Maymetsi tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Maymetsi is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and acute pancreatitis related to sitagliptin. Patients should seek immediate medical attention if they experience severe abdominal pain, unexplained fatigue, rapid breathing, or signs of an allergic reaction.

Maymetsi is contraindicated in patients with severe renal impairment, significant hepatic disease, or a history of lactic acidosis. It should also be avoided in individuals with known hypersensitivity to metformin, sitagliptin, or any of the tablet’s excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT